These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 29297732)

  • 21. Canagliflozin review - safety and efficacy profile in patients with T2DM.
    Jakher H; Chang TI; Tan M; Mahaffey KW
    Diabetes Metab Syndr Obes; 2019; 12():209-215. PubMed ID: 30787627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
    Neal B; Perkovic V; Mahaffey KW; Fulcher G; Erondu N; Desai M; Shaw W; Law G; Walton MK; Rosenthal N; de Zeeuw D; Matthews DR;
    Diabetes Obes Metab; 2017 Jul; 19(7):926-935. PubMed ID: 28244644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V
    J Am Soc Nephrol; 2019 Nov; 30(11):2229-2242. PubMed ID: 31530577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
    Blevins TC; Farooki A
    Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
    Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
    Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canagliflozin: metabolic, cardiovascular and renal protection.
    Barrios V; Escobar C
    Future Cardiol; 2021 May; 17(3):443-458. PubMed ID: 33538620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
    Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A
    Diabetes Obes Metab; 2023 Aug; 25(8):2331-2339. PubMed ID: 37184050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
    Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C
    Diabetes Obes Metab; 2023 Dec; 25(12):3724-3735. PubMed ID: 37671609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS.
    Borisov AN; Kutz A; Christ ER; Heim MH; Ebrahimi F
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2940-2949. PubMed ID: 37149821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program.
    Chen X; Hou X; Gao J; Yu X; Zeng W; Lv R; Yang X; Liu Y
    Diabetes Obes Metab; 2024 Mar; 26(3):878-890. PubMed ID: 38031821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis.
    Sinha B; Ghosal S
    Curr Diabetes Rev; 2020; 16(5):509-514. PubMed ID: 31652114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R
    Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
    Toto RD
    Nephron; 2017; 137(1):64-67. PubMed ID: 28743130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.
    Tobe SW; Mavrakanas TA; Bajaj HS; Levin A; Tangri N; Slee A; Neuen BL; Perkovic V; Mahaffey KW; Rapattoni W; Ang FG
    Diabetes Care; 2024 Mar; 47(3):501-507. PubMed ID: 38252809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.